| Randy W. Schekman | |
|---|---|
| Photo placeholder | |
| Affiliations | University of California, Berkeley |
| Country | USA |
| H-index | 180 |
| ORCID | 0000-0001-5393-1049 |
| Research Focus | Neurodegenerative Disease |
| Mechanisms | Vesicle Trafficking, [Autophagy](/mechanisms/autophagy-ad), Endoplasmic Reticulum |
Randy W. Schekman is a leading researcher in the field of neurodegenerative diseases, affiliated with University of California, Berkeley. Their research focuses on Vesicle Trafficking, Autophagy, Endoplasmic Reticulum, with particular emphasis on Neurodegenerative Disease. With an h-index of 180, Schekman is among the most cited researchers in the neuroscience field[1].
Schekman's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Neurodegenerative Disease. Their research group has made significant contributions to the fields of Vesicle Trafficking, Autophagy, Endoplasmic Reticulum, publishing in high-impact journals including PNAS.
Based at University of California, Berkeley, Schekman collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Schekman's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Neurodegenerative Disease. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant.
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
Within the Vesicle Trafficking, Autophagy, Endoplasmic Reticulum domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Recent PubMed-indexed publications (2024-present):
Primary institutional links: University of California, Berkeley. These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.
Membrane fusion in yeast. PNAS. 2001. ↩︎